治疗癌症和免疫相关疾病的新型腺素受体对手
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
介绍了针对腺A2a和A2b受体的新型抑制剂. 这些化合物为癌症和免疫相关疾病提供了潜在的治疗应用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 氨酸受体,特别是A2a和A2b亚型,在调节免疫反应和癌症进展方面发挥着至关重要的作用.
- 腺信号的失调与各种免疫相关疾病和瘤发生有关.
更多相关视频
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
06:19Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
相关概念视频
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
